
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
3
Neutral
5
Bullish
6
Bearish
26
Neutral
13
Bullish
7
Bearish
23
Neutral
8
Bullish
1
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
30 Cr
Low Risk
41.7
31.1
16.7
1.0
73.00
33.00
Sales CAGR
1Y
-60.83%
3Y
-2.68%
5Y
-1.60%
10Y
—
Profit CAGR
1Y
-43.79%
3Y
2.49%
5Y
22.20%
10Y
—
ROE
TTM
2.04%
3Y
3.81%
5Y
3.08%
10Y
—
ROCE
TTM
5.91%
3Y
10.46%
5Y
10.74%
10Y
—
Chandra Bhagat Pharma Ltd (CBPL) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Chandra Bhagat Pharma Limited focuses on marketing critical care and pharmaceutical products. It initially began as a private company in 2003, later becoming public in 2019. The company markets a diverse range of pharmaceutical formulations across major therapeutic categories, such as oncology, cardiology, and antibiotics. It has expanded its reach to both the domestic and international markets by obtaining necessary FDA approvals for its contract manufacturing. Mr. Hemant Bhagat, originally leading the company, has maintained focus on life-saving medicines, further expanding its portfolio through strategic marketing. Chandra Bhagat Pharma works with active pharmaceutical ingredients, promoting their use within India, while upholding a robust marketing infrastructure.
Over the past 52 weeks, Chandra Bhagat Pharma Ltd has traded between a low of ₹0.00 and a high of ₹73.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Chandra Bhagat Pharma Ltd has a market capitalization of approximately 29.57. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Chandra Bhagat Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 41.69 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
You can buy shares of Chandra Bhagat Pharma Ltd (CBPL) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.
Based on its market capitalization of 29.57 Cr, Chandra Bhagat Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Chandra Bhagat Pharma Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Chandra Bhagat Pharma Ltd is 41.69. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Chandra Bhagat Pharma Ltd currently does not pay dividends. Companies that do not pay dividends often reinvest profits to support business growth or strengthen operations.
Key risks associated with Chandra Bhagat Pharma Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Performance
STEADY PERFORMER
Valuation
OVERVALUED
Growth
STABLE
Profitability
MODERATE MARGIN
Technicals
Bearish
Risk
MODERATE RISK

Market Cap
₹ 30 Cr
P/E
41.69